BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27275407)

  • 1. Association of polymorphism in cytochrome P450 2C9 with susceptibility to head and neck cancer and treatment outcome.
    Yadav SS; Seth S; Khan AJ; Maurya SS; Dhawan A; Pant S; Pant MC; Parmar D
    Appl Transl Genom; 2014 Mar; 3(1):8-13. PubMed ID: 27275407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of cytochrome P450 2C9 polymorphism with locally advanced head and neck squamous cell carcinoma and response to concurrent cisplatin-based radical chemoradiation.
    Paul S; Chaudhuri T; Pant MC; Parmar D; Srivastava K
    South Asian J Cancer; 2014 Jul; 3(3):154-8. PubMed ID: 25136521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association and treatment response to capecitabine-based chemoradiotherapy with CYP2C9 polymorphism in head and neck cancer.
    Paul S; Pant MC; Parmar D; Verma J
    Indian J Cancer; 2011; 48(2):223-9. PubMed ID: 21768671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of drug metabolizing cytochrome P450 2D6 poor metabolizers with cytochrome P450 2C9 and 2C19 genotypes modify the susceptibility to head and neck cancer and treatment response.
    Yadav SS; Ruwali M; Pant MC; Shukla P; Singh RL; Parmar D
    Mutat Res; 2010 Feb; 684(1-2):49-55. PubMed ID: 19954746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of poor metabolizers of cytochrome P450 2C19 with head and neck cancer and poor treatment response.
    Yadav SS; Ruwali M; Shah PP; Mathur N; Singh RL; Pant MC; Parmar D
    Mutat Res; 2008 Sep; 644(1-2):31-7. PubMed ID: 18644391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms in drug-metabolizing enzymes and risk to head and neck cancer: evidence for gene-gene and gene-environment interaction.
    Maurya SS; Anand G; Dhawan A; Khan AJ; Jain SK; Pant MC; Parmar D
    Environ Mol Mutagen; 2014 Mar; 55(2):134-44. PubMed ID: 24519899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 2E1 and head and neck cancer: interaction with genetic and environmental risk factors.
    Ruwali M; Khan AJ; Shah PP; Singh AP; Pant MC; Parmar D
    Environ Mol Mutagen; 2009 Jul; 50(6):473-82. PubMed ID: 19334053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of genetic polymorphisms in glutathione S-transferases and susceptibility to head and neck cancer.
    Singh M; Shah PP; Singh AP; Ruwali M; Mathur N; Pant MC; Parmar D
    Mutat Res; 2008 Feb; 638(1-2):184-94. PubMed ID: 18035380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism in cytochrome P450 2A6 and glutathione S-transferase P1 modifies head and neck cancer risk and treatment outcome.
    Ruwali M; Pant MC; Shah PP; Mishra BN; Parmar D
    Mutat Res; 2009 Oct; 669(1-2):36-41. PubMed ID: 19406142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
    Topić E; Stefanović M; Samardzija M
    Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphism in cytochrome P4502A6 reduces the risk to head and neck cancer and modifies the treatment outcome.
    Yadav VK; Katiyar T; Ruwali M; Yadav S; Singh S; Hadi R; Bhatt MLB; Parmar D
    Environ Mol Mutagen; 2021 Nov; 62(9):502-511. PubMed ID: 34655463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphism in glutathione S-transferases: susceptibility and treatment outcome for head and neck cancer.
    Ruwali M; Singh M; Pant MC; Parmar D
    Xenobiotica; 2011 Dec; 41(12):1122-30. PubMed ID: 21957883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Polymorphisms of Cytochrome p450 (2C9) Enzyme in Patients with Type 2 Diabetes Mellitus in Turkmen and Fars Ethnic Groups.
    Rabiee M; Marjani A; Khajeniazi S; Mojerloo M
    Endocr Metab Immune Disord Drug Targets; 2018; 18(6):653-661. PubMed ID: 30129421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of cytochrome P450s with environmental risk factors increases their expression and risk to head and neck cancer.
    Katiyar T; Yadav V; Maurya SS; Hasan F; Singh AP; Yadav S; Singh S; Hadi R; Bhatt MLB; Parmar D
    Environ Mol Mutagen; 2022 Jun; 63(5):255-264. PubMed ID: 35638572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of cytochrome P450 2C9 activity in normal, healthy, adult Western Indian population by both phenotyping and genotyping.
    Swar BD; Bendkhale SR; Rupawala A; Sridharan K; Gogtay NJ; Thatte UM; Kshirsagar NA
    Indian J Pharmacol; 2016; 48(3):248-51. PubMed ID: 27298492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP1A2*1C, CYP2E1*5B, and GSTM1 polymorphisms are predictors of risk and poor outcome in head and neck squamous cell carcinoma patients.
    Olivieri EH; da Silva SD; Mendonça FF; Urata YN; Vidal DO; Faria Mde A; Nishimoto IN; Rainho CA; Kowalski LP; Rogatto SR
    Oral Oncol; 2009 Sep; 45(9):e73-9. PubMed ID: 19442564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ADH1C polymorphism modifies the risk of squamous cell carcinoma of the head and neck associated with alcohol and tobacco use.
    Peters ES; McClean MD; Liu M; Eisen EA; Mueller N; Kelsey KT
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):476-82. PubMed ID: 15734975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
    Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
    Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tobacco carcinogen-metabolizing genes CYP1A1, GSTM1, and GSTT1 polymorphisms and their interaction with tobacco exposure influence the risk of head and neck cancer in Northeast Indian population.
    Choudhury JH; Singh SA; Kundu S; Choudhury B; Talukdar FR; Srivasta S; Laskar RS; Dhar B; Das R; Laskar S; Kumar M; Kapfo W; Mondal R; Ghosh SK
    Tumour Biol; 2015 Aug; 36(8):5773-83. PubMed ID: 25724184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms.
    Yasar U; Lundgren S; Eliasson E; Bennet A; Wiman B; de Faire U; Rane A
    Biochem Biophys Res Commun; 2002 Nov; 299(1):25-8. PubMed ID: 12435384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.